PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF
in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin
lymphoma or Hodgkin disease.
Phase:
Phase 2
Details
Lead Sponsor:
GPCR Therapeutics, Inc. TaiGen Biotechnology Co., Ltd.